In conclusion, we newly introduced a quinazolin-4(3H)-one derivative, BIQO-19, which is an aurora kinase A inhibitor that exhibits an improved ADMET profile and antiproliferative activity in NSCLC cells. The gene discussed is AURKA; the disease is non-small cell lung carcinoma.